{"name":"Burning Rock Biotech","slug":"burning-rock","ticker":"BNR","exchange":"NASDAQ","domain":"burning-rock.com","description":"Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company offers next-generation sequencing (NGS)-based tissue, liquid biopsy cancer therapy selection, and prognosis prediction tests for various cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its key products include OncoScreen Focus, a multi-gene tumor mutation co-detection test kit for non-small cell lung cancer (NSCLC) patients; OncoScreen Plus, a pan-cancer test for tissue samples; OncoCompass Plus, a corresponding test for liquid biopsy samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; and ColonCore for assessin","hq":"Guangzhou, China","founded":0,"employees":"667","ceo":"Yusheng Han","sector":"Diagnostics / Cancer Genomics","stockPrice":17.37,"stockChange":0.54,"stockChangePercent":3.21,"marketCap":"$27M","metrics":{"revenue":79522486,"revenueGrowth":0.2,"grossMargin":74.7,"rdSpend":31824000,"netIncome":-47489000,"cash":71219000,"dividendYield":0,"peRatio":-29.9,"fiscalYear":"FY2024"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-08-28","type":"regulatory","headline":"Burning Rock Biotech Receives NMPA Approval for Its Liquid Biopsy Test","summary":"Burning Rock Biotech announced that it has received approval from the National Medical Products Administration (NMPA) for its liquid biopsy test, which is used to diagnose and monitor cancer patients.","drugName":"","sentiment":"positive"},{"date":"2024-03-28","type":"earnings","headline":"Burning Rock Biotech Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Burning Rock Biotech reported its financial results for the fourth quarter and full year 2023, with revenue increasing by 20% year-over-year.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxONlc0YVRMbGxkTkE3OVZQSFJCei1haG5TZmQ3VldvSVhhRlg2WGdKMWVQajZFREhRZkdLMm9FTGdzYUNOQUhzU3VTQV95TjR5Y28yRGROdVAtcFd6aUFNakwwVmpCSUkwR2hnQVZCX2NLTGk1cVZJVWdXUE1uWVBXb2VTaVpvVVMzOGNHTkRQUEJ2Q1BWcUhndWNlNHJobUgtNEEteWlaZlBiNzRSYVlqZGpJdmhDdm43ZkhDTTcxZXNZM2Q4Rnl5MGROQzQwX1hHZGR2UEpaTkZoUWhsaFN2c20tdHA?oc=5","date":"2026-03-13","type":"pipeline","source":"TipRanks","summary":"Burning Rock Biotech Narrows Loss and Lifts Margins on 2025 Results as Oncology Portfolio Advances - TipRanks","headline":"Burning Rock Biotech Narrows Loss and Lifts Margins on 2025 Results as Oncology Portfolio Advances","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxNTmJOVnVQdlhhWEFKT1k5NEUwaV9jRHVfcE5QbDNVZFVNNUZkZVRPSGYwcnRKVHAxYjFteHNjdDFTVkR4Nmt6ZGNGdzBUN3h4QWZxWXh0UG44aEFPRmIta1pWYlVBRnZyZkJzUm54c2xpdGlRUGN3aVJtQXZxbVZwTE45OHBpN1A3b01kanQ3UDdFYXhKQ0dJemRhcEVnZVNwWTJRVnl1aVkxX2FVRm9GSmlVOS11M3BiamM5c0dRZU5teWVmb3VqZ1NzaU53RDg?oc=5","date":"2026-03-13","type":"earnings","source":"Sahm","summary":"Burning Rock Biotech (BNR) Loss Reduction Trend Tests Bearish Profitability Concerns - Sahm","headline":"Burning Rock Biotech (BNR) Loss Reduction Trend Tests Bearish Profitability Concerns","sentiment":"neutral"},{"date":"2026-03-13","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: FORM 6-K","headline":"6-K Filing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxOZzNlbjMtR0tsR0xXc0N4NW5TdGhQbkZtSW1PeGhJVTVEd1RlNWdqbGVObmZiTEhSRDhQb0N5bTFLNU5iMlIyQWM1OHppY0FhNGVpYkhCbzJySEdVTWF4VGpSMXFlS3hqN1U2aWI2MmRITklZT0Foa2JZTWN0YUZDcDFTTWtpU1F1WkU3bGdDNTYybnBWd0JoYW9hbGlqMmF2YjRXQXJ6U2hLTEVVQkZNZzlhV1BJWFdnSGc?oc=5","date":"2026-03-12","type":"pipeline","source":"Stock Titan","summary":"Cancer DNA test firm Burning Rock slashes 2025 loss as margins climb - Stock Titan","headline":"Cancer DNA test firm Burning Rock slashes 2025 loss as margins climb","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQaVcxN2Fha3YwLWo2OW41TE82RE11RlpqNmROdmYydE5EbDg1TWE5VDNHX3hEVUJNU3RXSkdoOUhhT2pCUVdvY0RRZ0h4empfV3ZlYWgxa3RDU3hHWXFXN3lBa3lXa3pHYmtGdEpxbkp6MGdLRXBWTFRYaG9qQTVEN3hncFlUUGNkLVFKUElOOTNaVW9xNjhibXNIblAtQ0lWN1dVemk2TlJpWE5iRTY3S1p4MWl1ZV9ZQVBJ?oc=5","date":"2026-01-23","type":"pipeline","source":"Investing.com","summary":"Intel, Iris Energy among market cap stock movers on Friday - Investing.com","headline":"Intel, Iris Energy among market cap stock movers on Friday","sentiment":"neutral"},{"date":"2025-12-23","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: FORM 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2025-12-01","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: FORM 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2025-11-20","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: FORM 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2025-09-08","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: FORM 6-K","headline":"6-K Filing","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-07-16","type":"pipeline","source":"simplywall.st","summary":"3 Promising Penny Stocks With Market Caps Over $40M - simplywall.st","headline":"3 Promising Penny Stocks With Market Caps Over $40M","sentiment":"neutral"},{"date":"2025-06-06","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: FORM 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2025-04-29","type":"earnings","source":"SEC EDGAR","summary":"20-F filed with SEC: FORM 20-F","headline":"Annual Report (20-F) Filed","sentiment":"neutral"},{"date":"2025-03-25","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: FORM 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2024-12-31","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: FORM 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2024-12-04","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: FORM 6-K","headline":"6-K Filing","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Guardant Health","Invitae","Foundation Medicine"],"therapeuticFocus":["Cancer Genomics","Diagnostics"],"financials":{"source":"sec_edgar+yahoo","revenue":70667000,"revenuePeriod":"2024-12-31","revenueHistory":[{"value":70667000,"period":"2024-12-31"},{"value":75696000,"period":"2023-12-31"},{"value":81662000,"period":"2022-12-31"},{"value":79694000,"period":"2021-12-31"},{"value":65885000,"period":"2020-12-31"}],"grossProfit":49647000,"grossProfitHistory":[{"period":"2025-12-31","value":59382178.47778},{"period":"2024-12-31","value":53411153.448},{"period":"2023-12-31","value":53533038.17179},{"period":"2022-12-31","value":56010820.489029996}],"rdSpend":31824000,"rdSpendHistory":[{"period":"2025-12-31","value":24538180.41438},{"period":"2024-12-31","value":34235311.3533},{"period":"2023-12-31","value":51143832.298319995},{"period":"2022-12-31","value":62175652.54636}],"sgaSpend":42927151.23905,"operatingIncome":-8083153.17565,"operatingIncomeHistory":[{"period":"2025-12-31","value":-8083153.17565},{"period":"2024-12-31","value":-47520598.86464},{"period":"2023-12-31","value":-98645713.67817},{"period":"2022-12-31","value":-144494118.98038998}],"netIncome":-47489000,"netIncomeHistory":[{"period":"2025-12-31","value":-8156991.442419999},{"period":"2024-12-31","value":-51086353.40802},{"period":"2023-12-31","value":-96341841.84953},{"period":"2022-12-31","value":-143142038.62241}],"eps":-5.2,"epsHistory":[{"period":"2025-12-31","value":-5.2},{"period":"2024-12-31","value":-33.7},{"period":"2023-12-31","value":-63.8},{"period":"2022-12-31","value":-93.5}],"cash":71219000,"cashHistory":[{"period":"2025-12-31","value":70506259.71384},{"period":"2024-12-31","value":76616265.75273},{"period":"2023-12-31","value":90653937.19992},{"period":"2022-12-31","value":133446971.02826999}],"totalAssets":121288000,"totalLiabilities":42020163.826469995,"totalDebt":6355101.9224,"equity":78888155.73728,"operatingCashflow":-4191979.68411,"operatingCashflowHistory":[{"period":"2025-12-31","value":-4191979.68411},{"period":"2024-12-31","value":-13597589.48197},{"period":"2023-12-31","value":-37697751.27591},{"period":"2022-12-31","value":-67325171.59016}],"capex":-773606.91073,"capexHistory":[{"period":"2025-12-31","value":-773606.91073},{"period":"2024-12-31","value":-880900.8392899999},{"period":"2023-12-31","value":-1383030.52968},{"period":"2022-12-31","value":-10386730.24075}],"freeCashflow":-4965586.594839999,"dividendsPaid":null,"buybacks":0,"employees":667,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":11162400.49626,"ebit":-2136298.75615,"ebitda":-2136298.75615,"period":"2025-12-31","revenue":18616528.27755,"epsBasic":-1.5,"netIncome":-2267615.91322,"rdExpense":5138612.79282,"epsDiluted":-1.5,"grossProfit":14526831.541819999,"operatingIncome":-1774181.7472599999},{"sga":10833444.38562,"ebit":-2436368.03987,"ebitda":-2436368.03987,"period":"2025-09-30","revenue":19397946.422089998,"epsBasic":-1.6,"netIncome":-2469823.70166,"rdExpense":6111774.62013,"epsDiluted":-1.6,"grossProfit":14567803.67388,"operatingIncome":-2377415.33187},{"sga":10291668.9991,"ebit":-1694448.20969,"ebitda":-1694448.20969,"period":"2025-06-30","revenue":21894151.46058,"epsBasic":-0.9,"netIncome":-1429897.93254,"rdExpense":7335190.6929,"epsDiluted":-0.9,"grossProfit":15932411.482309999,"operatingIncome":-1694448.20969},{"sga":10639637.35807,"ebit":-2237107.8868299997,"ebitda":-2237107.8868299997,"period":"2025-03-31","revenue":19613860.71514,"epsBasic":-1.3,"netIncome":-1989653.895,"rdExpense":5952602.30853,"epsDiluted":-1.3,"grossProfit":14355131.77977,"operatingIncome":-2237107.8868299997},{"sga":12382868.933629999,"ebit":-6897466.836,"ebitda":-6897466.836,"period":"2024-12-31","revenue":18573345.41894,"epsBasic":-7.9,"netIncome":-11981253.61038,"rdExpense":7693770.53931,"epsDiluted":-7.9,"grossProfit":13179172.636939999,"operatingIncome":-6897466.836},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":17.37,"previousClose":16.83,"fiftyTwoWeekHigh":41.72,"fiftyTwoWeekLow":2.49,"fiftyTwoWeekRange":"2.487 - 41.72","fiftyDayAverage":18.64,"twoHundredDayAverage":17.18,"beta":1.5,"enterpriseValue":196002435.8283533,"forwardPE":-29.9,"priceToBook":2.32,"priceToSales":0.34,"enterpriseToRevenue":2.46,"enterpriseToEbitda":-40.03,"pegRatio":0,"ebitda":-4896169.781169999,"ebitdaMargin":-6.2,"freeCashflow":-3358370.11765052,"operatingCashflow":-4191979.68411,"totalDebt":6355101.9224,"debtToEquity":8.1,"currentRatio":2.99,"returnOnAssets":-4,"returnOnEquity":-9.9,"analystRating":"","recommendationKey":"none","numberOfAnalysts":0,"targetMeanPrice":0,"targetHighPrice":0,"targetLowPrice":0,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":4,"institutionHeldPercent":43.4,"sharesOutstanding":8813858,"floatShares":43063882,"sharesShort":47583,"shortRatio":1.56,"shortPercentOfFloat":0.4,"epsTrailing":-0.77,"epsForward":-0.58,"revenuePerShare":50.76,"bookValue":7.49,"officers":[{"age":46,"name":"Mr. Yusheng  Han","title":"Founder, Chairman & CEO"},{"age":41,"name":"Ms. Xiaozhi  Hu","title":"Vice President of Finance"},{"age":49,"name":"Dr. Zhihong  Zhang","title":"CTO & Director"},{"age":51,"name":"Mr. Hao  Liu","title":"Senior Advisor"},{"age":null,"name":"Dr. Xinru  Mao","title":"Senior VP of Pharma Biomarker & CDx. Services and International Diagnostics Division"}],"industry":"Diagnostics & Research","irWebsite":"","website":"https://www.brbiotech.com","phone":"86 20 3403 7871"}}